A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study)

BACKGROUND: Traditional first line regimens containing a non-nucleoside reverse transcriptase inhibitor or protease inhibitor may not be suitable for a subset of antiretroviral-naïve patients such as those with certain co-morbidities, women of child-bearing potential, and intolerability to component...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Princy N, Salvato, Patricia, LaMarca, Anthony, DeJesus, Edwin, Patel, Parul, McClernon, Daniel, Florance, Allison, Shaefer, Mark S
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2672933/
https://www.ncbi.nlm.nih.gov/pubmed/19358725
http://dx.doi.org/10.1186/1742-6405-6-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2672933/
https://www.ncbi.nlm.nih.gov/pubmed/19358725
http://dx.doi.org/10.1186/1742-6405-6-3

Ejemplares similares